Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants

In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.

In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.